Sarabi Mehrdad, Torshizian Ashkan, Khorasani Zahra Mazloum, Firoozi Abdollah, Majd Hassan Mehrad, Khoshhal Nastaran, Saeidi Nikoo, AkbariRad Mina
Student Research Committee, Faculty of Medicine Mashhad University of Medical Sciences Mashhad Iran.
Metabolic Syndrome Research Center Mashhad University of Medical Sciences Mashhad Iran.
Food Sci Nutr. 2025 May 1;13(5):e70146. doi: 10.1002/fsn3.70146. eCollection 2025 May.
It is debated that probiotics can improve glycolipid metabolism and slow the progression of prediabetes to diabetes mellitus. This study aimed to evaluate the effect of probiotics on lipid profile, glucose homeostasis, serum level of resistin, adiponectin, and vascular endothelial growth factor (VEGF) in prediabetic patients. This double-blind, randomized, placebo-controlled clinical trial was conducted on prediabetic patients in the Endocrinology clinic of Ghaem Hospital. Patients were randomly divided into two groups: the probiotics group was prescribed a daily 500-mg capsule of probiotics (10 colony-forming units), while the other received a placebo capsule with the same appearance. After 3 months, the effect of probiotic administration on laboratory parameters indicative of glycolipid metabolism, resistin, adiponectin, VEGF, body mass index (BMI), and blood pressure was compared between groups. This study was registered in the Iranian Registry of Clinical Trials (IRCT 20190801044405 N2). Fifty-two patients were included in the final analysis, with 26 patients in each group. The mean age of patients was 43.75 ± 8.45. At the beginning, both groups were similar in all demographic characteristics and measured serum levels of investigated biomarkers ( > 0.05 for all parameters). Both groups exhibited significant changes in BMI and fasting blood sugar (FBS). However, regarding FBS, the magnitude of change was significantly greater in patients treated with probiotics ( = 0.022). Our findings also revealed a significant increase in HDL ( = 0.001), adiponectin ( < 0.001), and VEGF ( = 0.024) serum levels and a significant decrease in HbA1c ( = 0.034), LDL ( = 0.002), TG ( < 0.001), and total cholesterol ( = 0.001) exclusively in the probiotics group. Probiotic supplementation efficiently improved glycolipid metabolism, adiponectin, and VEGF serum levels.
益生菌能否改善糖脂代谢并减缓糖尿病前期向糖尿病的进展存在争议。本研究旨在评估益生菌对糖尿病前期患者血脂谱、葡萄糖稳态、血清抵抗素、脂联素和血管内皮生长因子（VEGF）水平的影响。这项双盲、随机、安慰剂对照临床试验在加姆医院内分泌科门诊的糖尿病前期患者中进行。患者被随机分为两组：益生菌组每日服用一粒500毫克的益生菌胶囊（10个菌落形成单位），另一组服用外观相同的安慰剂胶囊。3个月后，比较两组间益生菌给药对指示糖脂代谢、抵抗素、脂联素、VEGF、体重指数（BMI）和血压的实验室参数的影响。本研究已在伊朗临床试验注册中心注册（IRCT 20190801044405 N2）。最终分析纳入了52名患者，每组26名。患者的平均年龄为43.75±8.45岁。开始时，两组在所有人口统计学特征和所测血清研究生物标志物水平方面均相似（所有参数P>0.05）。两组的BMI和空腹血糖（FBS）均有显著变化。然而，就FBS而言，益生菌治疗患者的变化幅度显著更大（P=0.022）。我们的研究结果还显示，仅益生菌组的高密度脂蛋白（HDL，P=0.001）、脂联素（P<0.001）和VEGF（P=0.024）血清水平显著升高，糖化血红蛋白（HbA1c，P=0.034）、低密度脂蛋白（LDL，P=0.002）、甘油三酯（TG，P<0.001）和总胆固醇（P=0.001）显著降低。补充益生菌可有效改善糖脂代谢、脂联素和VEGF血清水平。
